These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6779849)

  • 1. Isolation and characterization of tyrosinase inhibitors and their differential action on melanogenic subcellular compartments in amelanotic and melanomas.
    Imokawa G; Mishima Y
    Br J Dermatol; 1980 Dec; 103(6):625-33. PubMed ID: 6779849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinase and gamma-glutamyl transpeptidase in 5-s-cysteinyldopa genesis within melanotic and amelanotic melanomas.
    Mojamdar M; Ichihashi M; Mishima Y
    J Dermatol; 1982 Feb; 9(1):73-7. PubMed ID: 6124565
    [No Abstract]   [Full Text] [Related]  

  • 3. Isolation and biochemical characterization of tyrosinase-rich GERL and coated vesicle in melanin synthesizing cells.
    Imokawa G; Mishima Y
    Br J Dermatol; 1981 Feb; 104(2):169-78. PubMed ID: 6783060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of carbohydrate properties essential for melanogenesis in tyrosinases of cultured malignant melanoma cells by differential carbohydrate processing inhibition.
    Imokawa G
    J Invest Dermatol; 1990 Jul; 95(1):39-49. PubMed ID: 2114451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Isoenzymes of melanosomal tyrosinase isolated from transplanted hamster melanomas].
    Blagoeva PM; Ivanova TsIa
    Biokhimiia; 1984 May; 49(5):804-6. PubMed ID: 6430355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of structural properties for morphological differentiation of melanosomes: I. Purification of tyrosinase by tyrosine affinity chromatography and its characterization in B16 and Harding Passey melanomas.
    Jimbow K; Jimbow M; Chiba M
    J Invest Dermatol; 1981 Aug; 77(2):213-8. PubMed ID: 6792293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical characterization of tyrosinase inhibitors using tyrosinase binding affinity chromatography.
    Imokawa G; Mishima Y
    Br J Dermatol; 1981 May; 104(5):531-9. PubMed ID: 6786320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells.
    Halaban R; Cheng E; Zhang Y; Moellmann G; Hanlon D; Michalak M; Setaluri V; Hebert DN
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6210-5. PubMed ID: 9177196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in subcellular distribution of catechol-O-methyltransferase and tyrosinase in malignant melanoma.
    Shibata T; Pavel S; Smit NP; Mishima Y
    J Invest Dermatol; 1993 Feb; 100(2 Suppl):222S-225S. PubMed ID: 8433011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosinase inhibitors in amelanotic and melanotic malignant melanoma.
    Satoh GJ; Mishima Y
    Dermatologica; 1970; 140(1):9-14. PubMed ID: 4984430
    [No Abstract]   [Full Text] [Related]  

  • 11. Tyrosinase gene transcription and its control by melanogenic inhibitors.
    Ando S; Ando O; Suemoto Y; Mishima Y
    J Invest Dermatol; 1993 Feb; 100(2 Suppl):150S-155S. PubMed ID: 8433001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tyrosinase levels in amelanotic and melanotic melanoma cell cultures by a competitive enzyme-linked immunoadsorbent assay and by immunotitration analysis.
    Fuller BB; Iman DS; Lunsford JB
    J Cell Physiol; 1988 Jan; 134(1):149-54. PubMed ID: 3121644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of melanogenic properties in tyrosinases induced by glucosylation inhibitors within malignant melanoma cells.
    Imokawa G; Mishima Y
    Cancer Res; 1982 May; 42(5):1994-2002. PubMed ID: 6802485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
    Filimon A; Zurac SA; Milac AL; Sima LE; Petrescu SM; Negroiu G
    Melanoma Res; 2014 Jun; 24(3):219-36. PubMed ID: 24709887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody against human tyrosinase and reactive with melanotic and amelanotic melanoma cells.
    McEwan M; Parsons PG; Moss DJ
    J Invest Dermatol; 1988 Apr; 90(4):515-9. PubMed ID: 3127479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical characterization of three hamster melanoma variants--I. Tyrosinase activity and melanin content.
    Słomiński A; Scisłowski PW; Bomirski A
    Int J Biochem; 1984; 16(3):323-6. PubMed ID: 6421636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification of hamster melanoma tyrosinases and structural studies of their asparagine-linked sugar chains.
    Ohkura T; Yamashita K; Mishima Y; Kobata A
    Arch Biochem Biophys; 1984 Nov; 235(1):63-77. PubMed ID: 6437339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanogenesis in human melanomas.
    Chen YM; Chavin W
    Cancer Res; 1975 Mar; 35(3):606-12. PubMed ID: 803870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical demonstration of tyrosinase 4 in normal skin and melanocytic tumors].
    Kageshita T; Ono T; Arao T; Tomita Y
    Nihon Hifuka Gakkai Zasshi; 1987 May; 97(6):685-90. PubMed ID: 3114516
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulation of the cytosolic and melanosome-bound tyrosinase activities in Harding-Passey mouse melanoma.
    García-Borrón JC; Martinez JH; Arocas A; Solano F; Vicente V; Gómez S; Iborra JL; Lozano JA
    Int J Biochem; 1985; 17(9):995-1002. PubMed ID: 3934011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.